Bristol Myers Squibb (BMY) Q3 FY25 earnings call

Bristol-Myers Squibb delivered a strong third quarter, driven by robust performance across its growth portfolio and significant pipeline advancements. The company raised its full-year revenue guidance and maintained its EPS midpoint despite IPR&D charges, reflecting effective financial discipline and strategic investments. Management expressed confidence in the long-term growth trajectory, supported by upcoming clinical readouts and strategic business development activities, while actively navigating policy challenges like IRA.